Sunitinib
Description
Sunitinib is a tyrosine kinase inhibitor (TKI) medication used to treat certain types of cancer. It works by blocking the activity of specific proteins that promote cancer cell growth and blood vessel formation. Sunitinib is a targeted therapy, meaning it primarily affects cancer cells while minimizing damage to healthy cells. It is typically administered orally in pill form and is available in various dosages depending on the type of cancer being treated. Sunitinib has shown promising results in treating several cancers, including renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST), and pancreatic neuroendocrine tumors (pNET). It is a relatively well-tolerated drug, but like other chemotherapy medications, it can cause side effects, such as fatigue, nausea, diarrhea, and high blood pressure. The efficacy and safety of sunitinib are continually being investigated, with ongoing research focused on optimizing its use and exploring new applications for this targeted therapy.
Associated Diseases
- Renal cell carcinoma (RCC)
- Gastrointestinal stromal tumor (GIST)
- Pancreatic neuroendocrine tumors (pNET)
- Advanced renal cell carcinoma (RCC)
- Metastatic renal cell carcinoma (RCC)
- Progressive well-differentiated and/or poorly differentiated, locally advanced or metastatic, pancreatic neuroendocrine tumors (pNET)
- Advanced and/or metastatic GIST
Did you know?
Sunitinib was the first targeted therapy approved by the FDA for the treatment of advanced renal cell carcinoma.
